Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.
2.

PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.

Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK.

Mod Pathol. 2011 Mar;24(3):412-24. doi: 10.1038/modpathol.2010.176. Epub 2010 Oct 1.

3.

PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.

Long KB, Srivastava A, Hirsch MS, Hornick JL.

Am J Surg Pathol. 2010 May;34(5):723-9. doi: 10.1097/PAS.0b013e3181da0a20.

PMID:
20414099
4.

Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.

Koo J, Mertens RB, Mirocha JM, Wang HL, Dhall D.

Mod Pathol. 2012 Jun;25(6):893-901. doi: 10.1038/modpathol.2012.34. Epub 2012 Mar 2.

5.

Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.

Lorenzo PI, Jimenez Moreno CM, Delgado I, Cobo-Vuilleumier N, Meier R, Gomez-Izquierdo L, Berney T, Garcia-Carbonero R, Rojas A, Gauthier BR.

Histochem Cell Biol. 2011 Nov;136(5):595-607. doi: 10.1007/s00418-011-0866-3. Epub 2011 Sep 20.

6.

ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin.

Agaimy A, Erlenbach-Wünsch K, Konukiewitz B, Schmitt AM, Rieker RJ, Vieth M, Kiesewetter F, Hartmann A, Zamboni G, Perren A, Klöppel G.

Mod Pathol. 2013 Jul;26(7):995-1003. doi: 10.1038/modpathol.2013.40. Epub 2013 Mar 15.

7.

Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.

Lai JP, Mertens RB, Mirocha J, Koo J, Venturina M, Chung F, Mendez AB, Kahn M, Dhall D.

Endocr Pathol. 2015 Mar;26(1):54-62. doi: 10.1007/s12022-014-9346-3.

PMID:
25433656
8.

Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.

Weissferdt A, Tang X, Wistuba II, Moran CA.

Mod Pathol. 2013 Dec;26(12):1554-60. doi: 10.1038/modpathol.2013.111. Epub 2013 Jun 21.

9.

The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.

Koo J, Zhou X, Moschiano E, De Peralta-Venturina M, Mertens RB, Dhall D.

Endocr Pathol. 2013 Dec;24(4):184-90. doi: 10.1007/s12022-013-9264-9.

PMID:
24037217
10.

PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.

Tacha D, Qi W, Zhou D, Bremer R, Cheng L.

Appl Immunohistochem Mol Morphol. 2013 Jan;21(1):59-63. doi: 10.1097/PAI.0b013e318257cc1c.

PMID:
22595948
11.

A comprehensive analysis of PAX8 expression in human epithelial tumors.

Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS.

Am J Surg Pathol. 2011 Jun;35(6):816-26. doi: 10.1097/PAS.0b013e318216c112.

PMID:
21552115
12.

L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma.

Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, Fiegel HC, Petri S, Schachner M, Izbicki JR.

World J Gastroenterol. 2006 Jan 7;12(1):94-8.

13.

PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.

Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, Truong LD.

Mod Pathol. 2011 Jun;24(6):751-64. doi: 10.1038/modpathol.2011.3. Epub 2011 Feb 11.

14.

The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.

Liau JY, Tsai JH, Jeng YM, Kuo KT, Huang HY, Liang CW, Yang CY.

Appl Immunohistochem Mol Morphol. 2016 Jan;24(1):57-63. doi: 10.1097/PAI.0000000000000149.

PMID:
25710581
15.

Value of PAX 8 immunostaining in tumor diagnosis: a review and update.

Ordóñez NG.

Adv Anat Pathol. 2012 May;19(3):140-51. doi: 10.1097/PAP.0b013e318253465d. Review.

PMID:
22498579
16.

Napsin A expression in anaplastic, poorly differentiated, and micropapillary pattern thyroid carcinomas.

Chernock RD, El-Mofty SK, Becker N, Lewis JS Jr.

Am J Surg Pathol. 2013 Aug;37(8):1215-22. doi: 10.1097/PAS.0b013e318283b7b2.

PMID:
23681073
17.
18.

NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.

Woodard AH, Yu J, Dabbs DJ, Beriwal S, Florea AV, Elishaev E, Davison JM, Krasinskas AM, Bhargava R.

Am J Clin Pathol. 2011 Sep;136(3):428-35. doi: 10.1309/AJCPUFNMEZ3MK1BK.

PMID:
21846919
19.

Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.

Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R.

Mod Pathol. 2008 Feb;21(2):192-200. Epub 2007 Dec 14.

20.

Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.

Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A.

Am J Surg Pathol. 2008 Mar;32(3):420-5. doi: 10.1097/PAS.0b013e318158a397.

PMID:
18300808

Supplemental Content

Support Center